FDA ISO Data On CBD Safety In Supplements, Sees Potential As Well As Risks
You may also be interested in...
Recent statement that FDA has not found evidence supporting CBD as GRAS for use in human or animal food potentially points to NDI notifications as the only option manufacturers, marketers and other businesses will have to convince agency about safety for CBD and other hemp-derived substances used in dietary supplements.
As many as 100 ingredients are identified in hemp and cannabis plants, and FDA could be impeding even faster growth of CBD-containing supplement and food market by insisting that all those substances are the same as the CBD isolate active ingredient in Epidiloex, say FDLI's first conference entirely on regulation of cannabis and hemp products market.
In addition to FDA and FTC attention, pediatric claims by Rooted Apothecary could get attention of US lawmakers, who FDA is asking to authorize it to more directly enforce against adulterated supplements. Violative claims include “Increasing evidence suggests that CBD oil is a powerful option for pain and autism. It seems like an attractive and safe option for children.”